Biotech
News Category
Gerresheimer Opens New Plant in China, Doubling Production Capacity for Injectable Pharma Packaging
Gerresheimer has started operations at a new plant in Zhenjiang Dagang, China, doubling its production capacity for primary packaging for injectable p...
Helus Pharma Completes Enrollment in Phase 3 Depression Trial for HLP003
Helus Pharma has completed enrollment in its Phase 3 APPROACH trial for HLP003, a deuterated psilocin analogue for major depressive disorder, with res...
Darwin AG Renames to Novogenia AG, Aligning Corporate Identity with Core Brand
Darwin AG has officially changed its name to Novogenia AG, reinforcing its strategic focus on human genetics and personalized healthcare through its s...
NanoViricides Advances Oral Ebola Treatment NV-387 Toward Phase II Trial in DRC
NanoViricides reports progress on NV-387, a broad-spectrum oral antiviral candidate for Bundibugyo ebolavirus, with Phase II trial approval pending in...
Redwood AI Corp. Added to CSE25 Index, Boosting Visibility Among Investors
Redwood AI Corp. has been added to the CSE25 Index, which tracks the 25 largest companies on the Canadian Securities Exchange, potentially increasing ...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Depression Trial Enrollment Surpasses 88%
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for major depressive disorder, with topline data expected in Q4...
Quantum BioPharma Pursues Novel MS Treatment as Current Therapies Fall Short
Quantum BioPharma is developing Lucid-MS, a drug candidate aimed at repairing myelin damage in multiple sclerosis, as current treatments only slow dis...
Drug Delivery Innovation Emerges as Next Frontier in Oncology, Oncotelic's Deciparticle Platform Shows Promise
Oncotelic Therapeutics' nanoparticle-based drug delivery platform highlights a shift toward improving existing cancer therapies, potentially unlocking...
Quantum BioPharma Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Quantum BioPharma's Lucid-MS, a first-in-class drug candidate that protects myelin sheath, is preparing for Phase 2 trials after successful Phase 1 st...
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Targeting Solid Tumors
VERAXA Biotech announced in vitro proof-of-concept data for its BiTAC-ADC platform, showing selective killing of breast cancer cells while sparing hea...
Redwood AI Corp. Leverages AI to Accelerate Chemistry R&D Across Multiple Industries
Redwood AI Corp. is gaining attention as a 'One to Watch' for its AI-powered platforms that aim to speed up chemistry research and development in phar...
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin's Potential to Enhance Cancer Immunotherapy Responses
New research published in JCI Insight suggests that GeoVax's Gedeptin therapy could enhance immune checkpoint inhibitor responses and activate systemi...
Kairos Pharma Expands Oncology Pipeline with Acquisition of Phase 1-Ready c-MET Inhibitor
Kairos Pharma announces plans to acquire CL-741, a Phase 1-ready oral c-MET kinase inhibitor, to expand its oncology pipeline, while advancing clinica...
Platform Biotech Models Gain Traction as Drug-Delivery Market Approaches $410 Billion
As drug-delivery markets head toward $410 billion, biotech companies like Oncotelic Therapeutics are leveraging platform technologies to enhance exist...
GeoVax CEO Says Pharma Acquisitions Signal Renewed Strategic Focus on Vaccine Innovation and Health Security
GeoVax Labs' CEO David Dodd comments on recent pharmaceutical acquisitions by Eli Lilly, interpreting them as a strategic shift toward viewing vaccine...
Quantum BioPharma Highlights Lucid-MS and unbuzzd(TM) Growth on BioMedWire Podcast
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by addressing nerve damage, while its commercial product ...
Oragenics Advances Phase IIa Trial for Concussion Treatment, Explores CNS Device Licensing
Oragenics Inc. reported progress in its Phase IIa trial of ONP-002 for concussion and mild traumatic brain injury in Australia, plans to request a Typ...
Lantern Pharma Reports Q1 2026 Results, Advances AI Drug Development Platform and Clinical Pipeline
Lantern Pharma reported a 47% reduction in R&D spending while advancing key clinical trials and launching its AI drug development platform withZeta.ai...
BioStem Technologies Reports Q1 2026 Revenue of $6.1M, Advances Nasdaq Uplisting
BioStem Technologies reported first-quarter 2026 net revenue of $6.1 million, with a strategic shift toward hospital markets and progress on Nasdaq up...
Dogwood Therapeutics Reports First Quarter 2026 Results, Highlights Pipeline Progress
Dogwood Therapeutics announced first quarter 2026 financial results, with key pipeline milestones including Phase 2b data for Halneuron® expected this...
Tonix Pharmaceuticals to Present at Two Investor Conferences in May
Tonix Pharmaceuticals will participate in the RBC Capital Markets Global Healthcare Conference and A.G.P.'s Annual Virtual Healthcare Conference in Ma...
Lantern Pharma to Report First Quarter 2026 Financial Results on May 15
Lantern Pharma (NASDAQ: LTRN) will announce its first-quarter 2026 operating and financial results on May 15, providing updates on clinical trials and...
Kairos Pharma Sets Virtual Annual Meeting, Discloses Going Concern in Audit Report
Kairos Pharma Ltd. announced its virtual annual meeting and disclosed a going concern notice in its 2025 annual report, highlighting financial uncerta...
Annovis Bio CEO to Present Multi-Protein Alzheimer’s Research at Fierce Biotech Week 2026
Annovis Bio CEO Maria Maccecchini will present the company’s multi-protein approach to treating Alzheimer’s disease at Fierce Biotech Week 2026, highl...
BioStem Technologies to Report First Quarter 2026 Results on May 14
BioStem Technologies will release its first quarter 2026 financial results on May 14, 2026, followed by a conference call and webcast at 4:30 PM ET to...
Earth Science Tech Leverages Vertical Integration to Target Precision Medicine Market
Earth Science Tech Inc. (OTC: ETST) is building a vertically integrated platform combining compounding pharmacy, telemedicine, and clinical services t...
Lexaria Extends Material Transfer Agreement with PharmaCo for GLP-1 Drug Delivery Evaluation
Lexaria Bioscience has extended its Material Transfer Agreement with an undisclosed pharmaceutical company through 2026 to evaluate its DehydraTECH te...
Telomir Pharmaceuticals Closes TELI Acquisition, Secures Global Rights to Telomir-1
Telomir Pharmaceuticals (NASDAQ: TELO) has closed its acquisition of TELI Pharmaceuticals, securing sole global rights to Telomir-1 (Telomir-Zn) and e...